key: cord-0275421-c77g9mz7
authors: Tendulkar, P.; Pragya,; Panda, P. K.; Bhadoria, A. S.; Kulshreshtha, P.
title: Descriptive epidemiology of COVID-19 deaths during the first wave of pandemic in India - a single center experience
date: 2021-09-06
journal: nan
DOI: 10.1101/2021.09.01.21262791
sha: 73ddd3809af06f576b8171f8fb071b043a131023
doc_id: 275421
cord_uid: c77g9mz7

Background With the looming threat of recurrent waves of COVID-19 in the presence of mutated strains, its of paramount importance to understand the demographic and clinical attributes of COVID-19 related mortalities in each pandemic waves. This could help policy makers, public health experts, and clinicians to better plan preventive and management strategies to curb COVID-19 related mortality. Method This was a hospital record based, retrospective cross-sectional descriptive study, at a tertiary care hospital in Rishikesh, India. The study included all deceased patients between March 2020 and January 2021 (first wave) who tested positive for SARS-CoV-2 by RT-PCR and were hospitalized. The study was done to describe demography, clinical presentation, laboratory parameters, treatment given and associated complications of all COVID-19 deaths. Result Out of 424 mortalities, 298 (70.38%) were males and 126 (29.62%) were females. Mean age of patients was 55.85 (SD=16.24 years), out of which 19.5 percent were less than 45 years old, 33.6 percent were 45 to 60 years old and 41.8% were more than 60 years old. Comorbidity in the form of type 2 diabetes mellitus was present in 41.4% [95% CI (41.4-51.1)], hypertension in 39.8% [95% CI (35.1-44.6)], and coronary artery disease in 15.2% [95% CI (11.8-18.8)]. At the time of presentation, shortness of breath was present in 73.6% [95% CI (69.1-77.7)], fever in 64.92% [95% CI (60.1-69.4)], and cough in 46.1%, [95% CI (41.1-50.8)]. Deranged laboratory parameters were lymphopenia in 90.2% [95% CI (86.8-92.7)], transaminitis in 59.7% [95% CI (54.8-64.3)], and hypercreatinemia in 37.7% [95% CI (33.1-42.5)]. Complications manifested were acute respiratory distress syndrome in 78.3% [95% CI (74-82.1)] and shock in 54.7% [95% CI (49.8-59.5)]. Median time duration between onset of symptom and hospital admission was 5 days (IQR = 3-5 days) and median length of hospital stay was 9 days (IQR = 4-14 days). Conclusion During first pandemic wave, COVID-19 related mortality was 2.37 times higher among males, 2.14 times in age group >60 than <45 years. Most common associated comorbidities (>40%) were type 2 diabetes mellitus and hypertension. Most common associated symptoms (>60%) were shortness of breath and fever. Lymphopenia was seen in >90% cases while liver involvement in 60% and kidney in 38% cases. Median hospital stay was doubled the pre-hospital illness.

From January 2020 till February 2021 of first wave effects, September 2020 reported highest number of cases and causalities in India (MOHFW, India data on COVID-19). Seeing the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 6, 2021. 16 .24 years. out of which 19.5 percent were less than 45 years old, 33.6 percent were 45 to 60 years old and 41.8% were more than 60 years old. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 6, 2021. Median time duration between onset of symptom and hospital admission was 5 days (IQR = 3-8 days) and median length of hospital stay was 9 days (IQR = 4-14 days). (Figure 4 ).

As we are witnessing the current trend globally, mortality in the COVID-19 pandemic is very high. Strikingly, most deaths are seen in the male population than female. (1) (2) Results of a hospital based COVID related death study from United States shows that 60.6% of the deceased were males. (1) One review article supported the evidence that "ineffective anti-SARS-CoV-2 responses, coupled with a predisposition for inappropriate hyperinflammatory responses, could provide a biological explanation for the male bias in COVID-19 mortality". (3) The present study showed a similar trend, and out of total patients, 70.3% patients were males. Another explanation for higher mortality in males could be limited health care access to females leading to low footfalls in hospitals. (4) In the present study, around 42% of deceased were more than sixty year old. Earlier studies have also suggested that mortality is higher in elderly males. (1) (2) (5)(6) . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 6, 2021. ; https://doi.org/10.1101/2021.09.01.21262791 doi: medRxiv preprint Comorbidity also plays an essential role in any disease related mortality. A study done on Italian deceased patients has shown that, 35.5% of the deceased had diabetes, 30% had ischemic heart disease, 20.3% had active cancer, 24.5% had atrial fibrillation, 6.8% had dementia, and 34 (9.6%) had a history of stroke. (2) Results of another hospital-based study from southern India shows that diabetes (62%), hypertension (49.2%), and CAD (17.5%) were the commonly reported comorbidities. (7) Our study also shows similar findings with regard to comorbidities with diabetes being the most common comorbidity followed by hypertension, CAD, COPD, CKD, malignancy, chronic neurological disease, and CLD. In our study, 188 (44%) of the deceased had two or more comorbidities.

Dyspnoea was the most common presenting complain in the present study which is consistent with the finding of other studies. (8)(9) 73.6% had dyspnoea at presentation, and 78.3 % needed ICU admissions.

One of the studies in China showed that 83.2% of the patients had lymphopenia on admission. (10) Another Korean nationwide study concluded that lymphopenia at the time of initial presentation is associated with poorer prognosis in COVID-19 patients. (11) In the present study, 90.2% deceased patients had lymphopenia at the time of admission. One of the metanalyses showed that compared to moderate cases, severe COVID-19 cases had anaemia at presentation [weighted mean difference (WMD), -4.08 g/L (95% CI -5.12; -3.05). (12) 28.8% of the patients had a haemoglobin of ≤ 11 gm/dl at admission, The meta-analysis suggested that thrombocytopenia enhanced the risk of severe COVID-19 death by over fivefold. (13) One previous retrospective study suggested that both pre-renal and intrinsic AKI were associated with higher mortality. (14) Meta-analysis suggested that the risk of death in patients with AKI in COVID-19 increases significantly (OR 11.05, 95% CI (9.13-13.36)). (15) One of . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 6, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 6, 2021. ; https://doi.org/10.1101/2021.09.01.21262791 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 6, 2021. ; https://doi.org/10.1101/2021.09.01.21262791 doi: medRxiv preprint

Characteristics of Persons Who Died with COVID-19 -United States

Case-Fatality Rate and Characteristics of Patients Patients: A Retrospective Cohort Study

Risk factors and prognosis for COVID-19-induced acute kidney injury: A meta-analysis

AKI in Hospitalized Patients with COVID-19

Clinical characteristics of 2,459 severe or critically ill COVID-19 patients: A meta-analysis

Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis